Evidence you can defend.

Built for the market access landscape.

Quants is a health economics consultancy focused on HTA submissions, real-world evidence, and payer value communication for pharmaceutical companies. We build evidence packages that hold up under committee scrutiny.

What we do

Three disciplines, one objective

HTA Submissions

Cost-effectiveness models, budget impact analyses, and submission dossiers for HTA bodies.

CEA/CUA modelling
Extrapolation & uncertainty
Budget impact analysis
Dossier writing

Real-World Evidence

Registry-based research using Danish national health registries (NPR, CPR, DNPR, LSR). Epidemiology, treatment patterns, HCRU, and outcomes studies.

Registry study design
Statistical analysis
Manuscript preparation

Payer Value & Market Access

Payer value stories, competitive landscapes, and strategic positioning for market access teams. Systematic literature reviews, gap analyses, and evidence strategy.

Payer value stories
SLR & evidence synthesis
Gap analysis & evidence planning

How we work

From evidence gap to committee-ready

Assess

Systematic review of available evidence, gap analysis against HTA requirements, and strategic positioning of the value proposition.

Build

Health economic models, registry studies, evidence packages designed around the decision problem and the specific HTA body's requirements.

Defend

Transparent documentation, uncertainty quantification, and committee-ready materials where every assumption is traceable and defensible.

Team

Ole Henriksen

Partner · Health Economics & HTA

15+ years in health economics consulting. Deep expertise in HTA submissions, cost-effectiveness modelling, and budget impact analysis across oncology, rare diseases, and immunology. MSc Health Economics.

Klaus Zacchi Rindholt

Partner · AI Technology & Platform Architecture

25+ years in software architecture and IT management. Responsible for data infrastructure, analytical pipelines, and AI automation. Builds the technical platform that powers Quants' analytical capabilities.

Our approach

Every analysis we produce must be defensible under scrutiny. We don't optimise for a preferred outcome — we build evidence packages where methodology, data choices, and assumptions are transparently documented and aligned with current HTA standards.